ライフサイエンスコーパス: trandolapril

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 the angiotensin-converting enzyme inhibitor trandolapril.

2 chlorothiazide; and 4113 (52.4%) were taking trandolapril.

3 concise enantioselective formal synthesis of trandolapril.

4 Trandolapril and hydrochlorothiazide were used as added

5 Trandolapril and/or hydrochlorothiazide was administered

6 sustained release; 4934 (62.9%) were taking trandolapril; and 3430 (43.7%) were taking hydrochloroth

7 nts were randomly assigned to receive either trandolapril at a target dose of 4 mg per day (4158 pati

8 The verapamil-trandolapril-based strategy was as clinically effective

9 nificantly after 12 months of treatment with trandolapril compared with placebo.

10 Although trandolapril did not improve survival in the overall PEA

11 nt in the placebo group (hazard ratio in the trandolapril group, 0.96; 95 percent confidence interval

12 y revascularization--was 21.9 percent in the trandolapril group, as compared with 22.5 percent in the

13 thiazide or verapamil-SR (sustained release)/trandolapril in INVEST (INternational VErapamil SR Trand

14 The ACE inhibitor trandolapril may improve peripheral neuropathy in normot

15 ons between hs-CRP levels and the effects of trandolapril on any of the above outcomes.

16 eserved systolic function were randomized to trandolapril or placebo and followed up for a median of

17 lar ejection fraction who were randomized to trandolapril or placebo as part of the Prevention of Eve

18 ,627 patients with SIHD randomly assigned to trandolapril or placebo within the PEACE (Prevention of

19 ort, in which mean eGFR was relatively high, trandolapril reduced mortality in patients with reduced

20 tients in the top quartile of FGF-23 levels, trandolapril significantly reduced cardiovascular death

21 Trandolapril significantly reduced the risk of cardiovas

22 The INternational VErapamil-trandolapril STudy (INVEST) compared outcomes in hyperte

23 0 patients of the International Verapamil SR/Trandolapril Study (INVEST) Genetic Substudy (INVEST-GEN

24 objective of the International Verapamil SR/Trandolapril Study (INVEST) is to compare the risk for a

25 sis of data from the International Verapamil-Trandolapril Study (INVEST), which was conducted from Se

26 rticipants in the International Verapamil SR-Trandolapril Study (INVEST).

27 lapril in INVEST (INternational VErapamil SR Trandolapril STudy) were categorized into 3 groups on th

28 s (n=8290) were randomly assigned to receive trandolapril (target, 4 mg/d) or placebo.

29 The effect of trandolapril therapy on outcomes was not modified signif

30 Nevertheless, trandolapril therapy was associated with a significantly

31 Lower follow-up BP and addition of trandolapril to verapamil SR each were associated with r

32 Trandolapril was also recommended for patients with hear

33 Trandolapril was associated with a reduction in total mo

34 r blockade (candesartan) and ACE inhibition (trandolapril) were also tested in LTM.

35 0 mm Hg (HRs 0.82 or 0.70, respectively) and trandolapril with verapamil SR (HRs 0.78 and 0.79) were

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。